

ESMO-EANM ADVANCED COURSE PROGRAMME

DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF NUCLEAR MEDICINE IN ONCOLOGY

Essen, Germany
22-23 May 2024

CO-CHAIRS: Ken Herrmann, Germany
Aurelius G. Omlin, Switzerland

SPEAKERS: Eva Compérat, Austria
Désirée Deandreis, France
Wolfgang Fendler, Germany
Laura Graven, Netherlands
Viktor Grünwald, Germany
Jolanta A. Krajewska, Poland
Michael Nader, Germany
Marianne E. Pavel, Germany

LEARNING OBJECTIVES

- To get an updated analysis of the diagnostic and therapeutic applications of nuclear medicine in oncology
- To provide a knowledge of principles of both nuclear medicine modalities and systemic oncologic therapies in advanced trainees and specialists in oncology and nuclear medicine
- To provide an educational framework for in-depth analysis of the combined diagnostic/therapeutic strategies (theranostics) in oncology and scientific interaction between oncology and nuclear medicine experts
- To foster interdisciplinary exchange and collaboration in both nuclear medicine imaging and nuclear medicine treatment applications

Wednesday, 22 May 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and Learning Objectives Introduction
Ken Herrmann, DE and Aurelius G. Omlin, CH

09:10-10:50 **Session 1 - Introduction to Theranostics and Systemic Therapies**
Chairs: Désirée Deandreis, FR and Jolanta A. Krajewska, PL

20' Definitions and therapeutic concepts of therapeutic radionuclides
Ken Herrmann, DE

20' Regulatory challenges in the development of theranostics
Michael Nader, DE

20' Radioiodine therapy in thyroid cancer
Désirée Deandreis, FR

20'	Landscape of systemic therapies for thyroid malignancies Jolanta A. Krajewska, PL
20'	Discussion
10:50-11:20	Coffee break
11:20-12:20	Workshop session Workshop session where clinical cases are presented by speakers with interactive questions and discussion with the audience
Workshop 1	Thyroid malignancies Jolanta A. Krajewska, PL and Désirée Deandreis, FR
12:20-13:20	Lunch
13:20-14:40	Session 2 - NETs as role model for theranostics Chairs: Ken Herrmann, DE and Marianne E. Pavel, DE
20'	Overview NET (Epidemiology, disease specific characteristics and challenges) Laura Graven, NL
20'	PRRT in NET – What is the standard? Wolfgang Fendler, DE
20'	Systemic therapies for NETs (other than PRRT) Marianne E. Pavel, DE
20'	Discussion
14:40-15:10	Coffee break
15:10-16:50	Session 3 - Expanding theranostics to prostate cancer Chairs: Laura Graven, NL and Aurelius G. Omlin, CH
20'	Biology in advanced prostate cancer with a special focus on PSMA across the disease spectrum (primary tumour, upregulation with AR targeted therapies, heterogeneity etc) Eva Compérat, AT
20'	Treatment landscape in advanced prostate cancer Aurelius G. Omlin, CH
20'	How to make best use of PSMA RLT in advanced prostate cancer – Status May 2024 Ken Herrmann, DE
20'	Future of PSMA RLT outside of prostate cancer Viktor Grünwald, DE
20'	Discussion and Conclusion of Day 1
19:30	Networking Dinner

Thursday, 23 May 2024

9:00-12:30

Workshop sessions

Workshop sessions where clinical cases are presented by speakers with interactive questions and discussion with the audience

60' Workshop time

Workshop 2

How to build and run a theranostic unit
Laura Graven, NL and Ken Herrmann, DE

Workshop 3

NET theranostics
Wolfgang Fendler, DE and Marianne E. Pavel, DE

11:00-11:30

Coffee break

Workshop 4

Prostate cancer RL: Selection and monitoring of patients on treatment
Ken Herrmann, DE and Aurelius G. Omlin, CH

12:30-13:00

Conclusion & Farewell

Ken Herrmann, DE and Aurelius G. Omlin, CH

13:00-14:00

Lunch